[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR086773A1 - Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo - Google Patents

Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo

Info

Publication number
AR086773A1
AR086773A1 ARP120102306A ARP120102306A AR086773A1 AR 086773 A1 AR086773 A1 AR 086773A1 AR P120102306 A ARP120102306 A AR P120102306A AR P120102306 A ARP120102306 A AR P120102306A AR 086773 A1 AR086773 A1 AR 086773A1
Authority
AR
Argentina
Prior art keywords
hydrocarbon radical
hydrocarbon chain
substituted
derivatives
group
Prior art date
Application number
ARP120102306A
Other languages
English (en)
Inventor
Ma Xiaohui
Jin Yuanpeng
Han Min
Zhou Shuiping
Zhou Wangyi
Luo Xuejun
Wang Guocheng
Yan Lulu
Zhang Lanlan
Zhu Yonghong
Original Assignee
Tasly Pharmaceutical Group Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tasly Pharmaceutical Group Co filed Critical Tasly Pharmaceutical Group Co
Publication of AR086773A1 publication Critical patent/AR086773A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/52—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describe también el método para preparar las cinamamidas sustituidas y sus derivados de la presente. Se seleccionan derivados de piperonal como materiales de partida para preparar los derivados de cinamamida sustituida de la presente mediante una reacción de Wittig y una reacción de condensación ácido-amina, Además, se describe un uso de los presentes compuestos para prevenir y tratar enfermedades mentales de tipo depresivo. Reivindicación 1: Un compuesto de una fórmula general (1) y sus sales de adición de ácido farmacéuticamente aceptables, en donde, R¹ es H, OH, F, Cl, Br, I, OCH₃, OCF₃, OCHF₂, OCH₂F, CF₃, CHF₂, CH₂F, CH₃, CH₃CH₂, CF₃CH₂, CN, NO₂, NH₂ ó COOR³; dicho R³ es H, una cadena hidrocarbonada lineal C₁₋₁₀, una cadena hidrocarbonada ramificada C₃₋₁₀, un radical hidrocarbonado cíclico C₃₋₁₀ ó un radical hidrocarbonado aromático C₆₋₁₀; n representa 0, 1, 2 ó 3, y la unidad representada por la formula (2) contiene al menos un enlace carbono-carbono simple o doble; X es =O, =S, H, SH ó SR³; Y es N o NR³, O ó S, donde R³ es H, una cadena hidrocarbonada lineal C₁₋₁₀, una cadena hidrocarbonada ramificada C₃₋₁₀, un radical hidrocarbonado cíclico C₃₋₁₀ ó un radical hidrocarbonado aromático C₆₋₁₀; R² es H, una cadena hidrocarbonada lineal C₁₋₁₀, una cadena hidrocarbonada ramificada C₃₋₁₀, un radical hidrocarbonado cíclico C₃₋₁₀, un radical hidrocarbonado aromático C₆₋₁₀, un grupo alcohol alquilo C₁₋₁₀ o un grupo de derivados de piperazina N-sustituido; o R² es un grupo que forma un grupo tetrahidropirrolilo, piperidilo o hexametilenimino con el Y vecino.
ARP120102306A 2011-06-27 2012-06-27 Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo AR086773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110174376 2011-06-27
CN201210123842.7A CN102850317B (zh) 2011-06-27 2012-04-25 一种取代桂皮酰胺衍生物、制备方法及其应用

Publications (1)

Publication Number Publication Date
AR086773A1 true AR086773A1 (es) 2014-01-22

Family

ID=47397349

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102306A AR086773A1 (es) 2011-06-27 2012-06-27 Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo

Country Status (12)

Country Link
US (1) US10071989B2 (es)
EP (1) EP2725018B1 (es)
JP (1) JP6078059B2 (es)
KR (2) KR101861656B1 (es)
CN (2) CN102850317B (es)
AR (1) AR086773A1 (es)
AU (1) AU2012276114B2 (es)
CA (1) CA2838495C (es)
RU (1) RU2587668C2 (es)
TW (1) TWI579277B (es)
WO (1) WO2013000399A1 (es)
ZA (1) ZA201400188B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102850317B (zh) * 2011-06-27 2017-02-08 天士力制药集团股份有限公司 一种取代桂皮酰胺衍生物、制备方法及其应用
CN103242284B (zh) * 2012-02-01 2015-12-16 天士力制药集团股份有限公司 一种钯催化的5-三氟甲基胡椒醛的合成方法
CN104513172B (zh) * 2013-09-30 2018-02-02 天士力医药集团股份有限公司 含有三氟甲基的酰胺生物碱、制备方法及其药物用途
EP2918270A1 (de) * 2014-03-12 2015-09-16 Symrise AG Aromatische Alkensäurederivate zur Appetithemmung und Stimmungsaufhellung
CN104003839B (zh) * 2014-06-05 2015-11-25 褚朝森 一种肉桂酸或其衍生物的制备方法
CN105708797B (zh) * 2014-12-05 2020-03-17 天士力医药集团股份有限公司 一种取代桂皮酰胺衍生物的自乳化载药系统
CN107011313B (zh) 2016-01-27 2021-11-30 天士力医药集团股份有限公司 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用
CN107837301B (zh) * 2017-11-01 2021-05-28 苏州颐华生物医药技术股份有限公司 一种大叶蒟提取物及其制备方法与应用
JP2024521282A (ja) 2021-05-28 2024-05-31 天士力医薬集団股分有限公司 抗うつ・抗不安の置換桂皮アミド化合物
CN114163373A (zh) * 2021-12-02 2022-03-11 中国人民解放军联勤保障部队第九0四医院 一种治疗抑郁症的酰胺类生物碱及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH583730A5 (es) * 1973-09-25 1977-01-14 Wander Ag Dr A
CA1242718A (en) 1983-11-21 1988-10-04 John R. Carson Acetylene derivatives and methods for the treatment of hypertension and angina
AU2005201481A1 (en) 1999-03-24 2005-05-05 The Regents Of The University Of California Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
CN1389462A (zh) * 2002-07-12 2003-01-08 复旦大学 大叶蒟素及其同系物，和在制备药物组合物中的应用
KR20050051691A (ko) 2002-10-11 2005-06-01 아스트라제네카 아베 1,4-이치환 피페리딘 유도체 및 11-베타ｈｓｄ1억제제로서의 이들의 용도
CN100436407C (zh) * 2003-03-20 2008-11-26 蒋毅 大叶蒟有效部位的制备及其在医疗、保健领域的应用
WO2005016883A2 (en) 2003-08-14 2005-02-24 Icos Corporation Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
KR100675619B1 (ko) 2005-08-11 2007-01-30 영남대학교 산학협력단 미백 활성을 갖는 피퍼롱구미닌 화합물의 신규 제조방법
CN100532182C (zh) 2005-12-31 2009-08-26 财团法人工业技术研究院 四轮车的车轮配置结构
WO2008028314A1 (fr) * 2006-08-07 2008-03-13 Lotus Pharmaceutical Co., Ltd. Dérivés de catéchol, composition et application associées
JP5294481B2 (ja) 2009-06-25 2013-09-18 三和シヤッター工業株式会社 トンネル用避難扉
JP5644274B2 (ja) * 2009-08-31 2014-12-24 大日本印刷株式会社 塩基発生剤、感光性樹脂組成物、当該感光性樹脂組成物からなるパターン形成用材料、当該感光性樹脂組成物を用いたパターン形成方法並びに物品
CN102244558B (zh) 2010-05-12 2014-09-03 华为技术有限公司 发送数据的方法及装置
CN102240281B (zh) * 2010-05-12 2014-05-14 天士力制药集团股份有限公司 5′-甲氧基-3′，4′-次甲二氧基桂皮酸异丁基酰胺在制备抗抑郁药物中的应用
CN102850317B (zh) * 2011-06-27 2017-02-08 天士力制药集团股份有限公司 一种取代桂皮酰胺衍生物、制备方法及其应用

Also Published As

Publication number Publication date
WO2013000399A1 (zh) 2013-01-03
CN103687850A (zh) 2014-03-26
TWI579277B (zh) 2017-04-21
CN103687850B (zh) 2016-03-09
CA2838495A1 (en) 2013-01-03
JP6078059B2 (ja) 2017-02-08
US20140121242A1 (en) 2014-05-01
ZA201400188B (en) 2017-08-30
CN102850317B (zh) 2017-02-08
EP2725018B1 (en) 2017-04-19
KR20140036294A (ko) 2014-03-25
CA2838495C (en) 2018-06-05
US10071989B2 (en) 2018-09-11
RU2014102302A (ru) 2015-08-10
RU2587668C2 (ru) 2016-06-20
JP2014523886A (ja) 2014-09-18
KR20170082641A (ko) 2017-07-14
AU2012276114A1 (en) 2014-01-09
EP2725018A4 (en) 2015-05-20
AU2012276114B2 (en) 2016-08-04
TW201309666A (zh) 2013-03-01
KR101861656B1 (ko) 2018-05-28
NZ618801A (en) 2015-12-24
CN102850317A (zh) 2013-01-02
EP2725018A1 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo
UY31050A1 (es) Antagonistas de trpv1 y usos de los mismos
CU20110145A7 (es) Derivados de sulfonamida
CO2017007679A2 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
AR082101A1 (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
UY32490A (es) Inhibidores de beta-secretasa
ECSP14004812A (es) Triazolopiridinas sustituidas
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP15002066A (es) Inhibidores de virus de hepatitis c
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
CU20110052A7 (es) Compuestos orgánicos
UY32848A (es) Compuestos heterocíclicos de oxima
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
UY33452A (es) Triazolopiridinas sustituidas
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR067770A1 (es) Derivados de tiazol y ditiazol para el tratamiento de diabetes
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration